View of IN-SILICO REPURPOSING OF FDA-APPROVED HEPATITIS C DRUGS, VELPATASVIR AND BOCEPREVIR, AGAINST THE OMICRON VARIANT SPIKE GLYCOPROTEIN

Return to Article Details IN-SILICO REPURPOSING OF FDA-APPROVED HEPATITIS C DRUGS, VELPATASVIR AND BOCEPREVIR, AGAINST THE OMICRON VARIANT SPIKE GLYCOPROTEIN Download Download PDF